Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer’s Disease
The Food and Drug Administration granted traditional approval of lecanemab for the treatment of Alzheimer’s disease (AD). Lecanemab is a humanized anti-amyloid monoclonal antibody directed towards Aβ protofibrils. Lecanemab is the only drug that targets Aβ soluble protofils and has shown statistica...
Shranjeno v:
| Principais autores: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
University of Minnesota Libraries Publishing
2024-03-01
|
| Serija: | INNOVATIONS in Pharmacy |
| Teme: | |
| Online dostop: | https://pubs.lib.umn.edu/index.php/innovations/article/view/5787 |
| Oznake: |
Brez oznak, prvi označite!
|